tetano
Editor, Senior Moderator
Arch Virol
. 2021 Jan 18.
doi: 10.1007/s00705-021-04958-7. Online ahead of print.
The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV
Nima Hemmat[SUP] 1 [/SUP], Zahra Asadzadeh[SUP] #[/SUP][SUP] 1 [/SUP], Noora Karim Ahangar[SUP] #[/SUP][SUP] 1 [/SUP], Hajar Alemohammad[SUP] #[/SUP][SUP] 1 [/SUP], Basira Najafzadeh[SUP] #[/SUP][SUP] 1 [/SUP], Afshin Derakhshani[SUP] 1 2 [/SUP], Amir Baghbanzadeh[SUP] 1 [/SUP], Hossein Bannazadeh Baghi[SUP] 1 3 4 [/SUP], Darya Javadrashid[SUP] 1 [/SUP], Souzan Najafi[SUP] 1 [/SUP], Meriadeg Ar Gouilh[SUP] 5 6 [/SUP], Behzad Baradaran[SUP] 7 8 [/SUP]
Affiliations
Abstract
The number of descriptions of emerging viruses has grown at an unprecedented rate since the beginning of the 21[SUP]st[/SUP] century. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is the third highly pathogenic coronavirus that has introduced itself into the human population in the current era, after SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). Molecular and cellular studies of the pathogenesis of this novel coronavirus are still in the early stages of research; however, based on similarities of SARS-CoV-2 to other coronaviruses, it can be hypothesized that the NF-κB, cytokine regulation, ERK, and TNF-α signaling pathways are the likely causes of inflammation at the onset of COVID-19. Several drugs have been prescribed and used to alleviate the adverse effects of these inflammatory cellular signaling pathways, and these might be beneficial for developing novel therapeutic modalities against COVID-19. In this review, we briefly summarize alterations of cellular signaling pathways that are associated with coronavirus infection, particularly SARS-CoV and MERS-CoV, and tabulate the therapeutic agents that are currently approved for treating other human diseases.
. 2021 Jan 18.
doi: 10.1007/s00705-021-04958-7. Online ahead of print.
The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV
Nima Hemmat[SUP] 1 [/SUP], Zahra Asadzadeh[SUP] #[/SUP][SUP] 1 [/SUP], Noora Karim Ahangar[SUP] #[/SUP][SUP] 1 [/SUP], Hajar Alemohammad[SUP] #[/SUP][SUP] 1 [/SUP], Basira Najafzadeh[SUP] #[/SUP][SUP] 1 [/SUP], Afshin Derakhshani[SUP] 1 2 [/SUP], Amir Baghbanzadeh[SUP] 1 [/SUP], Hossein Bannazadeh Baghi[SUP] 1 3 4 [/SUP], Darya Javadrashid[SUP] 1 [/SUP], Souzan Najafi[SUP] 1 [/SUP], Meriadeg Ar Gouilh[SUP] 5 6 [/SUP], Behzad Baradaran[SUP] 7 8 [/SUP]
Affiliations
- PMID: 33462671
- DOI: 10.1007/s00705-021-04958-7
Abstract
The number of descriptions of emerging viruses has grown at an unprecedented rate since the beginning of the 21[SUP]st[/SUP] century. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is the third highly pathogenic coronavirus that has introduced itself into the human population in the current era, after SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). Molecular and cellular studies of the pathogenesis of this novel coronavirus are still in the early stages of research; however, based on similarities of SARS-CoV-2 to other coronaviruses, it can be hypothesized that the NF-κB, cytokine regulation, ERK, and TNF-α signaling pathways are the likely causes of inflammation at the onset of COVID-19. Several drugs have been prescribed and used to alleviate the adverse effects of these inflammatory cellular signaling pathways, and these might be beneficial for developing novel therapeutic modalities against COVID-19. In this review, we briefly summarize alterations of cellular signaling pathways that are associated with coronavirus infection, particularly SARS-CoV and MERS-CoV, and tabulate the therapeutic agents that are currently approved for treating other human diseases.